Boston Scientific Corp. (NYSE:BSX)

CAPS Rating: 2 out of 5

The Company develops, manufactures & markets medical devices that are used in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology & neuromodulation.

Results 1 - 20 of 197 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar plowboy (< 20) Submitted: 2/1/2014 1:58:59 PM : Outperform Start Price: $13.55 BSX Score: -20.28

turnaround

Recs

0
Member Avatar simonwmich (< 20) Submitted: 1/18/2014 5:36:14 PM : Outperform Start Price: $13.82 BSX Score: -18.03

Stock has almost tripled over the past year and game changing technologies forthcoming with 1H14 expected launch of Watchman A Fib device. Company could also benefit the most from MDT Simplicity renal denervation failure.

Recs

0
Member Avatar hammerpants (< 20) Submitted: 4/12/2013 1:16:47 AM : Outperform Start Price: $7.68 BSX Score: +34.34

Bsx has been the red headed stepchild for too long. Sure - interventional cardiology and crm isn't as glamorous as it once was, but there is still plenty of lettuce to be made. Business is finally leaner and out from under a lot of dead weight and regulatory trouble, still some improvements to go, but solid sales and distribution channels are there. A few technology breakthroughs or acquisitions away from blowing it away.

Recs

0
Member Avatar IfHeDiesHeDies (74.33) Submitted: 4/8/2013 7:23:52 PM : Outperform Start Price: $7.84 BSX Score: +29.44

lOVE IT.

Recs

0
Member Avatar akim088 (< 20) Submitted: 7/27/2012 8:20:04 AM : Outperform Start Price: $5.02 BSX Score: +97.87

coronary stents are still doing well. Market leader in less invasive procedures which I believe is the future of the medicine. Pipeline is still strong. JNJ still drooling over CRM side of BSX. Just waiting to ripe....

Recs

0
Member Avatar demasom (< 20) Submitted: 7/2/2012 3:25:07 PM : Outperform Start Price: $5.81 BSX Score: +64.57

ObamaCare

Recs

0
Member Avatar ttodisco (< 20) Submitted: 6/27/2012 8:49:20 AM : Outperform Start Price: $5.55 BSX Score: +70.20

eps going up

Recs

0
Member Avatar bradford86 (99.72) Submitted: 1/10/2012 11:19:43 PM : Outperform Start Price: $5.53 BSX Score: +66.78

255. Boston Scientific (NYSE: BSX) is bottoming. Target: $6-$7. Now is a good time to buy. I'll be voting on this with my caps points. Sure, it is cheap and it lacks catalysts. At this point, the catalyst is effectively a rhetorical question: "who is going to sell?" Since stock prices are a function of daily supply and demand, I expect that the lack of selling at these prices and the bottoming effect will drive the stock into my price range. Eventually, at prices low enough, investors kind of look around at each other and decide that selling doesn't make sense. At that point, you don't need catalysts for upside because you get a self-fulfilling bottoming prophecy that does it on its own.

http://beta.fool.com/bradford86/2012/01/10/price-market-part-37/

Recs

0
Member Avatar Danimal82 (< 20) Submitted: 10/18/2011 4:17:18 PM : Outperform Start Price: $5.66 BSX Score: +53.96

New stent coming Q411/Q112 (one in which 40% proceeds won't be going to Abbott), good pipeline/recent aquisitions, forward looking strategy, slowly but surely driving down debt, still a buyout possiblity (new president/CEO-to-be from JNJ..).

Recs

0
Member Avatar jnations92 (< 20) Submitted: 7/8/2011 1:58:43 PM : Outperform Start Price: $7.15 BSX Score: +23.36

Widespread hearing loss in the younger generations will boost sales of Boston Scientific's hearing aid division

Recs

0
Member Avatar joelecr (< 20) Submitted: 5/19/2011 12:40:17 PM : Underperform Start Price: $7.11 BSX Score: -25.24

Debt load

Recs

0
Member Avatar pgraff101 (< 20) Submitted: 2/18/2011 3:39:26 PM : Outperform Start Price: $7.51 BSX Score: +15.55

Big money is all in on this one.

Recs

0
Member Avatar yanks129 (< 20) Submitted: 2/18/2011 7:58:54 AM : Outperform Start Price: $7.40 BSX Score: +18.14

doing the right things

Recs

0
Member Avatar HollowMountain (< 20) Submitted: 2/6/2011 11:17:13 AM : Outperform Start Price: $6.99 BSX Score: +24.45

Important technology in an area of explosive growth and a huge budget for R&D. Debt could be a problem, but this company makes a huge amount of money and it appears that it could reach all of it's obligations if it came down to it.

Recs

0
Member Avatar nomo001 (< 20) Submitted: 12/27/2010 9:03:53 PM : Outperform Start Price: $7.65 BSX Score: +3.11

Under-appreciated stock on Wall Street. Strong Defibrillator and stent business.

Recs

0
Member Avatar hoperalot1 (< 20) Submitted: 12/17/2010 3:26:24 PM : Outperform Start Price: $6.78 BSX Score: +16.49

This one has been beaten down too long. Now transitioning to being a profitable, progressive company. Easily a 10 within 6 months

Recs

0
Member Avatar ardski (< 20) Submitted: 10/20/2010 1:59:18 PM : Outperform Start Price: $6.50 BSX Score: +20.51

New line of products in future.

Recs

0
Member Avatar nogolf (82.95) Submitted: 7/26/2010 11:47:12 AM : Outperform Start Price: $5.98 BSX Score: +27.02

New stent roll out marks significant campaign to regain market share and lost stature. 50% gain in 6 mos.

Recs

0
Member Avatar showthemoney (< 20) Submitted: 6/24/2010 11:20:53 AM : Underperform Start Price: $5.93 BSX Score: -22.91

This nag has been beat bad, but you losers just hang in there waiting for a turn around until your investments are totally gone. This company has lost all hope and respect.

Recs

0
Member Avatar 1ct (82.36) Submitted: 6/14/2010 12:55:46 PM : Outperform Start Price: $5.85 BSX Score: +30.03

BSX has dropped the ball recently, but the game is early. Can't ignore the merger buyout possibilites or Valuation . BSX should have the ability to play the game on its own, regardless of the potential of merger/buyout play. No more fumbles.

Featured Broker Partners


Advertisement